Rilan Bai

1.3k total citations · 1 hit paper
36 papers, 920 citations indexed

About

Rilan Bai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rilan Bai has authored 36 papers receiving a total of 920 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Rilan Bai's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (8 papers). Rilan Bai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (8 papers). Rilan Bai collaborates with scholars based in China, United States and Kenya. Rilan Bai's co-authors include Jiuwei Cui, Zheng Lv, Dongsheng Xu, Lingyu Li, Naifei Chen, Huimin Tian, Ling Bai, Wei Song, Xiaohong Chen and Ying Meng and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Cancer Letters.

In The Last Decade

Rilan Bai

35 papers receiving 911 citations

Hit Papers

Predictive biomarkers for cancer immunotherapy with immun... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    2020 318 citations Rilan Bai, Zheng Lv et al. Biomarker Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rilan Bai China 13 567 306 247 240 171 36 920
Regula Deurloo Switzerland 5 468 0.8× 153 0.5× 215 0.9× 316 1.3× 222 1.3× 12 947
Federica Biello Italy 20 634 1.1× 154 0.5× 418 1.7× 267 1.1× 292 1.7× 56 994
Aiqin Gao China 16 577 1.0× 669 2.2× 208 0.8× 391 1.6× 289 1.7× 38 1.3k
Satoshi Muto Japan 18 406 0.7× 229 0.7× 311 1.3× 246 1.0× 223 1.3× 72 898
Keyi Jia China 13 441 0.8× 234 0.8× 196 0.8× 276 1.1× 111 0.6× 27 730
Xin Yi China 16 359 0.6× 127 0.4× 288 1.2× 331 1.4× 232 1.4× 66 837
Baolan Li China 12 613 1.1× 174 0.6× 325 1.3× 218 0.9× 119 0.7× 35 868
Martin Rees United Kingdom 11 490 0.9× 338 1.1× 111 0.4× 460 1.9× 230 1.3× 17 973

Countries citing papers authored by Rilan Bai

Since Specialization
Citations

This map shows the geographic impact of Rilan Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rilan Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rilan Bai more than expected).

Fields of papers citing papers by Rilan Bai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rilan Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rilan Bai. The network helps show where Rilan Bai may publish in the future.

Co-authorship network of co-authors of Rilan Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Rilan Bai. A scholar is included among the top collaborators of Rilan Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rilan Bai. Rilan Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bai, Rilan, et al.. (2024). ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal Cancer. Molecular Carcinogenesis. 63(12). 2401–2413. 4 indexed citations
3.
4.
Bai, Rilan & Jiuwei Cui. (2024). Regulation of fatty acid synthase on tumor and progress in the development of related therapies. Chinese Medical Journal. 137(16). 1894–1902. 5 indexed citations
5.
Bai, Rilan, et al.. (2024). Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors. Chinese Journal of Cancer Research. 36(4). 421–441. 1 indexed citations
6.
Bai, Rilan, Ying Meng, & Jiuwei Cui. (2023). Therapeutic strategies targeting metabolic characteristics of cancer cells. Critical Reviews in Oncology/Hematology. 187. 104037–104037. 10 indexed citations
7.
Bai, Rilan & Jiuwei Cui. (2023). Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria. Cancer Letters. 564. 216223–216223. 47 indexed citations
8.
Meng, Ying, Rilan Bai, & Jiuwei Cui. (2023). Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies. Thoracic Cancer. 14(13). 1121–1134. 12 indexed citations
9.
Bai, Rilan, Wenqian Li, & Jiuwei Cui. (2022). Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. Cancer Biology and Medicine. 19(12). 1–13. 3 indexed citations
10.
Cui, Jiuwei, Qing Zhou, Shun Lü, et al.. (2021). The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. Translational Lung Cancer Research. 10(8). 3594–3607. 2 indexed citations
11.
Bai, Rilan, Naifei Chen, Xiao Chen, et al.. (2021). Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biology and Medicine. 18(4). 1118–1133. 27 indexed citations
12.
Bai, Rilan, et al.. (2021). Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Hepatobiliary & pancreatic diseases international. 21(1). 10–24. 1 indexed citations
13.
Bai, Rilan, Zheng Lv, Chen Xiao, et al.. (2020). Precision Detection Technology: Equipping Precision Oncology with Wings. Journal of Oncology. 2020. 1–8. 5 indexed citations
14.
Bai, Rilan, Lingyu Li, Xiaohong Chen, et al.. (2020). Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer. Frontiers in Oncology. 10. 575472–575472. 45 indexed citations
15.
Bai, Rilan, Naifei Chen, Lingyu Li, et al.. (2020). Mechanisms of Cancer Resistance to Immunotherapy. Frontiers in Oncology. 10. 1290–1290. 249 indexed citations
16.
Bai, Rilan, Zheng Lv, Dongsheng Xu, & Jiuwei Cui. (2020). Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research. 8(1). 34–34. 318 indexed citations breakdown →
17.
18.
Li, Wenqian, Rilan Bai, & Jiuwei Cui. (2019). Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis. SHILAP Revista de lepidopterología. 2 indexed citations
19.
Tang, Ribo, Xueliang Yan, Jianzeng Dong, et al.. (2014). Predictors of recurrence after a repeat ablation procedure for paroxysmal atrial fibrillation: role of left atrial enlargement. EP Europace. 16(11). 1569–1574. 25 indexed citations
20.
Tang, Ribo, Jianzeng Dong, Deyong Long, et al.. (2014). Incidence and clinical characteristics of transient ST-T elevation during transseptal catheterization for atrial fibrillation ablation. EP Europace. 17(4). 579–583. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Regula Deurloo Breakdown of academic impact, for papers by Federica Biello Breakdown of academic impact, for papers by Aiqin Gao Breakdown of academic impact, for papers by Satoshi Muto Breakdown of academic impact, for papers by Keyi Jia Breakdown of academic impact, for papers by Xin Yi Breakdown of academic impact, for papers by Baolan Li Breakdown of academic impact, for papers by Martin Rees
Rankless by CCL
2026